Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia , with or without Richter’s Transformation , responded to treatment 1 GLPG5201 showed no cytokine... | June 5, 2023

Related Keywords

Germany ,Mechelen ,Region Flamande ,Belgium ,Japan ,Sandra Cauwenberghs ,Margotj Pont ,Leticia Alserawan ,Marieke Vermeersch ,Nuria Martinez Cibrian ,Daniel Estban ,Mercedes Montoro ,Van Gijsel ,Julio Delgado ,Jeevan Shetty ,Christian Jacques ,Valentin Ortiz Maldonado ,Sergi Betriu ,Exchange Commission ,European Hematology Association ,Head Of Clinical Development Oncology At Galapagos ,Objective Response Rate ,Clinical Development Oncology ,Clinical Results ,Maike Spoon ,Bayesian Optimal Interval ,Cancer Journal ,Galapagos Nv Stock Exchange ,News ,Information ,Press Release ,Wall , ,Nut ,F ,Eligible ,Patients ,Ith ,Hronic ,Lymphocytic ,Leukemia ,Dr ,Without ,Transformation ,Esponded ,O ,Treatment ,Howed ,O Glpg Be0003818359 ,